The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Understanding the cardioprotective effects of flavonols. Heart attack and stroke are a major cause of death and disablement in Australia. Current therapies do not treat the underlying causes of these diseases. In this project we will investigate a promising new drug treatment for these diseases and will determine how this poorly understood drug acts to reduce damage to the heart. This project will lead to new treatments for cardiovascular diseases and will enhance our understanding of the causes ....Understanding the cardioprotective effects of flavonols. Heart attack and stroke are a major cause of death and disablement in Australia. Current therapies do not treat the underlying causes of these diseases. In this project we will investigate a promising new drug treatment for these diseases and will determine how this poorly understood drug acts to reduce damage to the heart. This project will lead to new treatments for cardiovascular diseases and will enhance our understanding of the causes of these disease states.Read moreRead less
Structure-activity relationships in the development of new bioactive isoflavonoids. This project aims to develop new chemical substances based on the structure of a group of naturally occuring compounds called isoflavones. Biological activity related to chronic inflammatory (eg arthritis) and heart disease will be examined in cells and animal models. This information will be used to design compounds with enhanced activity. The eventual aim is to develop potential therapeutic agents to treat chr ....Structure-activity relationships in the development of new bioactive isoflavonoids. This project aims to develop new chemical substances based on the structure of a group of naturally occuring compounds called isoflavones. Biological activity related to chronic inflammatory (eg arthritis) and heart disease will be examined in cells and animal models. This information will be used to design compounds with enhanced activity. The eventual aim is to develop potential therapeutic agents to treat chronic inflammatory and cardiovascular disease.Read moreRead less
Mannosyl transfer processes in leishmania and mycobacteria. The human diseases leishmaniasis and tuberculosis are caused by infectious microorganisms. We will target pathways to the biosynthesis and degradation of parasite-specific mannose containing metabolites that play essential roles in the ability of these pathogens to cause disease. We will develop new ways to study these pathways, and will synthesize novel substrates and inhibitors that will allow the development of antituberculosis and a ....Mannosyl transfer processes in leishmania and mycobacteria. The human diseases leishmaniasis and tuberculosis are caused by infectious microorganisms. We will target pathways to the biosynthesis and degradation of parasite-specific mannose containing metabolites that play essential roles in the ability of these pathogens to cause disease. We will develop new ways to study these pathways, and will synthesize novel substrates and inhibitors that will allow the development of antituberculosis and antileishmanial drugs. This project will contribute to our national competitiveness in the newly emerging area of chemical biology.Read moreRead less
Mannose metabolism in pathogenic microorganisms. Current treatments for tuberculosis and leishmaniasis are failing due to chronic underinvestment by the private sector and public agencies over many decades. The causative agents, the microorganisms Leishmania spp and Mycobacterium tuberculosis, respectively, use sugar processing pathways that differ from humans, and thus represent targets for new drugs. We will study two related sugar-processing biochemical pathways in these organisms. We will de ....Mannose metabolism in pathogenic microorganisms. Current treatments for tuberculosis and leishmaniasis are failing due to chronic underinvestment by the private sector and public agencies over many decades. The causative agents, the microorganisms Leishmania spp and Mycobacterium tuberculosis, respectively, use sugar processing pathways that differ from humans, and thus represent targets for new drugs. We will study two related sugar-processing biochemical pathways in these organisms. We will develop new ways to measure enzyme activity using mass spectrometry, and new reagents to clone several biosynthetic enzymes. Our work will lay a foundation for new antibiotics to combat these insidious diseases, and will foster Australian expertise in chemical biology and innovative basic science.Read moreRead less
Total Synthesis of the Microsclerodermins: Anti-fungal Cyclic Peptides. Fungal infections are one of the major causes of morbidity and mortality in the increasing immunocompromised patient population, which includes AIDS, chemotherapy and organ transplant patients. The aim of this project is to discover new anti-fungal treatments for drug-resistant pathogenic fungal infections, based on the microsclerodermin family of natural products. The small quantity of microsclerodermin isolated from the na ....Total Synthesis of the Microsclerodermins: Anti-fungal Cyclic Peptides. Fungal infections are one of the major causes of morbidity and mortality in the increasing immunocompromised patient population, which includes AIDS, chemotherapy and organ transplant patients. The aim of this project is to discover new anti-fungal treatments for drug-resistant pathogenic fungal infections, based on the microsclerodermin family of natural products. The small quantity of microsclerodermin isolated from the natural environment hampers the development of anti-fungal agents from this natural product. Innovative synthetic methods will be developed to prepare large quantities of microsclerodermins and related compounds for biological testing, thereby furthering the development of this promising class of anti-fungal drugs.Read moreRead less
Inhibitors of enzymes in the lysine biosynthetic pathway. Recent reports of increasing bacterial resistance to antibiotics highlight the need for continual development of new antibacterial agents. Inhibitors of the biosynthesis of the amino acid lysine - an essential component of bacterial proteins and cell wall - may provide a novel class of antibiotics. This project describes investigations of the mechanism of the first two enzymes in the lysine biosynthetic pathway and the design and synthesi ....Inhibitors of enzymes in the lysine biosynthetic pathway. Recent reports of increasing bacterial resistance to antibiotics highlight the need for continual development of new antibacterial agents. Inhibitors of the biosynthesis of the amino acid lysine - an essential component of bacterial proteins and cell wall - may provide a novel class of antibiotics. This project describes investigations of the mechanism of the first two enzymes in the lysine biosynthetic pathway and the design and synthesis of inhibitors of these enzymes.Read moreRead less
Allosteric modulators as novel probes of G-Protein coupled receptor function. This research will provide novel mechanistic understanding on the function of one of the largest protein families in the mammalian genome, and the most important family with respect to drug targets. The insights gained thus have direct relevance to drug discovery. The discovery of novel G protein-coupled receptor (GPCR) allosteric enhancers will not only lead to potentially new therapeutic agents, but can significant ....Allosteric modulators as novel probes of G-Protein coupled receptor function. This research will provide novel mechanistic understanding on the function of one of the largest protein families in the mammalian genome, and the most important family with respect to drug targets. The insights gained thus have direct relevance to drug discovery. The discovery of novel G protein-coupled receptor (GPCR) allosteric enhancers will not only lead to potentially new therapeutic agents, but can significantly value-add to other national research efforts focusing on GPCR structural biology.Read moreRead less
Design and Development of HIV-1 Integrase Inhibitors Based on a Natural Product Lead. HIV/AIDS is a significant health problem with over 40 million people infected with HIV worldwide. Resistance to current drugs is rising rapidly and new therapeutics are urgently needed. This project will bring together local expertise in organic synthesis and virology in order to develop new and better treatments for HIV/AIDS. Ultimately, Australians with HIV may benefit directly from anti-HIV compounds produce ....Design and Development of HIV-1 Integrase Inhibitors Based on a Natural Product Lead. HIV/AIDS is a significant health problem with over 40 million people infected with HIV worldwide. Resistance to current drugs is rising rapidly and new therapeutics are urgently needed. This project will bring together local expertise in organic synthesis and virology in order to develop new and better treatments for HIV/AIDS. Ultimately, Australians with HIV may benefit directly from anti-HIV compounds produced and may also benefit from advances in our understanding of this elusive virus resulting from the project.Read moreRead less
Raman and synchrotron spectroscopy of nano-scale drug interactions and molecular processes in single living cells. The need for potent low-cost drugs is ever increasing, yet effective ways to screen for new drugs remain elusive. A spectroscopic approach to screening drugs in living cells would seem a logical alternative to chemically based and morphological methods that are the status quo. In this context we are developing methodology to analyse molecular target sites in single living cells for ....Raman and synchrotron spectroscopy of nano-scale drug interactions and molecular processes in single living cells. The need for potent low-cost drugs is ever increasing, yet effective ways to screen for new drugs remain elusive. A spectroscopic approach to screening drugs in living cells would seem a logical alternative to chemically based and morphological methods that are the status quo. In this context we are developing methodology to analyse molecular target sites in single living cells for two of the most devastating diseases to afflict human kind, namely malaria and cancer. New ways of rapidly screening drugs in living cells prior to clinical trials will save an enormous amount of time, money and ultimately lives.Read moreRead less
Australian Laureate Fellowships - Grant ID: FL0992138
Funder
Australian Research Council
Funding Amount
$3,100,000.00
Summary
Towards antibacterials without resistance. Innovative automation technologies will be used to create and investigate a revolutionary new approach to disable pathogenic superbugs, bacteria resistant to multiple antibiotics. The chemicals created and proteins evaluated in this research program will advance fundamental knowledge about the molecular weapons that bacteria produce to cause disease; deliver social and economic benefits to Australia through the development of potential new antibacterial ....Towards antibacterials without resistance. Innovative automation technologies will be used to create and investigate a revolutionary new approach to disable pathogenic superbugs, bacteria resistant to multiple antibiotics. The chemicals created and proteins evaluated in this research program will advance fundamental knowledge about the molecular weapons that bacteria produce to cause disease; deliver social and economic benefits to Australia through the development of potential new antibacterial treatments; contribute to Australia's continued international leading role in drug discovery research; enhance international links and attract industry investment in Australia; and provide a stimulating research training environment to inspire and motivate the next generation of scientists.Read moreRead less